Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ligand Pharmaceuticals Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
LGND
Nasdaq
2834
www.ligand.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ligand Pharmaceuticals Incorporated
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 6th, 2025 12:00 pm
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
- Jan 13th, 2025 9:00 am
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year
- Dec 27th, 2024 12:01 pm
LGND: 2025 View Calls for 17% Topline Growth
- Dec 16th, 2024 9:35 am
Ligand price target raised to $151 from $135 at Oppenheimer
- Dec 12th, 2024 12:45 pm
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
- Dec 10th, 2024 2:00 pm
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
- Nov 16th, 2024 2:09 pm
Ligand to Present at Stifel 2024 Healthcare Conference
- Nov 14th, 2024 1:00 pm
LGND: 3Q Sales Surprise to the Upside
- Nov 11th, 2024 8:00 am
Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 9th, 2024 12:14 pm
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price
- Nov 8th, 2024 12:11 pm
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
- Nov 8th, 2024 7:11 am
Ligand: Q3 Earnings Snapshot
- Nov 7th, 2024 12:48 pm
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Nov 7th, 2024 12:00 pm
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
- Nov 1st, 2024 12:01 pm
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
- Oct 23rd, 2024 8:01 pm
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
- Oct 17th, 2024 11:30 am
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
- Oct 9th, 2024 9:06 pm
LGND: Initiating Coverage – A Prince Among Royalty
- Oct 9th, 2024 9:24 am
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
- Sep 25th, 2024 11:46 am
Scroll